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Background
One hundred years ago, diabetes was considered to be
one disease, although with marked clinical heterogeneity.
Adults who developed diabetes could often manage for
years with diet alone, but children usually died within 6
months of diagnosis [1]. Once discovered, insulin was
used successfully to treat these children. Thereafter,
these children were classified as having insulin-
dependent diabetes, which was later re-termed as type 1
diabetes with a dependence on insulin to survive.
Patients with all types of diabetes were classified as
having non-insulin-dependent or type 2 diabetes,
although many eventually required insulin treatment
themselves, despite their less aggressive disease course.
The development of radioimmunoassays for insulin,
proinsulin and its cleaved section C-peptide, only tended
to confirm that children with diabetes had little or no
insulin, while adults often had substantial amounts. This
binary approach to diabetes stratification i.e., that
patients do or do not secrete insulin has recently been
challenged, notably by exploiting immunogenetics and
more sensitive protein assays to define the diabetes
spectrum and its heterogeneity [1–3].
C-peptide spectrum
In their BMC Medicine article, McKeigue and col-
leagues [4] explored detectable C-peptide in a large
cohort from Scotland, representing a cross-sectional
analysis of one-third of the population diagnosed with
type 1 diabetes over age 16 years. Patients were
diagnosed both clinically, by exclusion of other
causes, and with one or more diabetes-associated
autoantibody. Detectable C-peptide levels varied sub-
stantially, with age and disease duration being key
variables: C-peptide was lowest in the youngest 15
years from diagnosis (19%) and highest in the oldest,
close to diagnosis (92%). Genetic analysis using single
nucleotide polymorphisms indicated some heritability
for C-peptide variance (26%) [4]. As expected, both
human leucocyte antigen (HLA) and insulin gene
regions reflected the most aggressive disease process.
Persistence of C-peptide was associated with gene risk
scores for both type 1 and type 2 diabetes, but also
strikingly with HLA regions, not accounted for by
high gene-risk HLA serotypes. In other words, the
genetics of C-peptide persistence may be distinct
from the genetics of C-peptide loss, invoking multiple
genetic networks linked to both type 1 and type 2
diabetes.
This paper opens a can of worms regarding our
understanding of diabetes and its stratification. The
apparent categorical difference between the two major
types of diabetes has been challenged, with the
realisation that some adult-onset type 1 diabetes cases
may not initially need insulin treatment and can have
similar C-peptide levels as in type 2 cases [1, 3]. The
characteristic type 1 diabetes inflammatory infiltrate,
or insulitis, turns out to be not so prevalent as
thought, and has been dubbed ‘the elusive lesion’ [5].
Indeed, islet beta-cell function and mass may be
compromised in multiple ways, e.g. apoptosis and de-
differentiation. There may also be many mechanisms
to explain the persistence of C-peptide secretion,
including new growth, trans-differentiation with the
appearance of islet delta cells or, perhaps, distinct
beta-cells, impervious to aggressive autoimmune
attack [5]. However, any explanation must account
for the remarkable spectrum of C-peptide, in which
decline follows a pattern of ‘younger, faster, greater’,
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while C-peptide persistence is also associated with
genes distinct from type 1 diabetes susceptibility
genes, implicating type 2 diabetes networks [4].
‘Stunned’ beta-cells
At first glance, there appears to be a hierarchy of beta-cell
dysfunction. We now know that proinsulin is retained,
even as C-peptide response declines. However, when C-
peptide is low or absent, both C-peptide and proinsulin
fail to respond to stimuli [6]. Given histological evidence
that beta-cells persist long after diagnosis, the question
arises: are these beta-cells ‘sleeping’ and could they be
aroused? In other words, are they ‘stunned’, or function-
ally dead [5, 7]? The fact that proinsulin levels are detect-
able, even when C-peptide is not, supports the former
argument [6]. Since proinsulin, C-peptide and insulin are
secreted in equimolar quantities, but insulin is largely ex-
tracted by the liver, increased proinsulin:C-peptide (PL:
CP) ratios imply accumulation and secretion of inad-
equately processed proinsulin, a hallmark of endoplasmic
reticulum (ER) dysfunction. A cell that is unable to re-
spond to its primary stimulus is called a ‘stunned’ cell and
has the intrinsic capacity to restore competence [7]. In the
context of diabetes, one feature of such ‘stunned’ cells, is
that there is not only a mismatch between insulin
secretion and glucose stimulus, but also that the change
can recover. ‘Stunned’ beta-cells are probably a feature of
both type 2 and type 1 diabetes and can anticipate and
predict both types [7]. Such ‘stunned’ cells are concep-
tually distinct from ER stress, although both imply a
dysfunctional beta-cell. Indeed, evidence of ER stress,
using this PL:CP ratio, can be found in children at risk
of type 1 diabetes and, in them, predicts the disease,
especially in children under the age of 10 years [6, 7].
Clinical implications
Many years ago, we and others found the same altered
PL:CP ratio: before type 1 diabetes, but also in identical
co-twins of children with type 1 diabetes and in non-
HLA identical siblings, who were themselves estimated
to be at low disease risk [8, 9]. Such an altered PL:CP
ratio also predicated type 1 diabetes [10]. Despite using
different immunoassays, these changes in PL:CP ratio
give the results coherence, although none can be
certain it was entirely intact proinsulin that was being
measured [6, 8–10]. The idea that changes in PL:CP
ratio could be familial raises the possibility that shared
genetic and/or environmental effects play a role in
beta-cell susceptibility to damage. That much would be
consistent with the evidence in the present paper that
persistence of C-peptide, as against decline, is both
genetically determined and associated with type 2
diabetes gene risk [4].
Conclusions
The present data open new avenues for research and
hints at various pathways that might have a differential
impact on disease risk, rate of disease progression and
failure of the disease process to eliminate all beta-cells in
the pancreatic islets. Whether sleeping or dead, the
possibility that some cells are ‘not drowning, but
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